|
|
DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
A. Buisson
,
M. Nachury
,
Mathurin Fumery
,
T. Guilmoteau
,
E. Leclerc
,
et al.
Article dans une revue
hal-03665871v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Effectiveness of Switching from Intravenous to Subcutaneous Infliximab in Patients with Inflammatory Bowel Diseases: The REMSWITCH Study.
A. Buisson
,
M. Nachury
,
M. Reymond
,
Clara Yzet
,
P. Wils
,
et al.
Article dans une revue
hal-03760901v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
A. Buisson
,
Mathurin Fumery
,
M. Serrero
,
L. Orsat
,
S. Nancey
,
et al.
2020, pp.S337-S338
Autre publication scientifique
hal-03551532v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
A. Buisson
,
M. Nachury
,
M. Reymond
,
Clara Yzet
,
P. Wils
,
et al.
Journal of Crohn's and Colitis, 2022, 16 (1), pp.I393-I394
Article dans une revue
hal-03665861v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
French validation of the Quality of life in Essential Tremor Questionnaire (QUEST) and the Essential Tremor Embarrassment Assessment (ETEA)
A. Marques
,
I. Rieu
,
B. Pereira
,
G. Castelnovo
,
F. Fluchère
,
et al.
Article dans une revue
hal-04213230v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|